,56,60 We and others have previously shown that oncogenic drivers can confer PARPi sensitivity to leukemia cells because of their impacts on HR (eg, AML1-ETO, promyelocytic leukemia-retinoic acid receptor alpha, ten-eleven translocation 2),40,61 or can be targeted when PARPis are used in combination with other therapeutics (eg, MLL fusions).40 Here, KMT2A is linked to leukemia.